国家医保局开展真实世界医保综合价值评价试点

Core Insights - The establishment of the National Credible Evaluation Point Network for Real-World Medical Insurance Comprehensive Value Assessment aims to scientifically evaluate the actual value of pharmaceutical products using real clinical data [1][2] - The initiative involves 79 leading medical institutions and is intended to support key decisions in medical insurance, including drug negotiations and pricing [1] - The network will provide objective evidence for the adjustment of the medical insurance catalog, ensuring that the benefits and cost-effectiveness of negotiated drugs are in line with initial expectations [1] Group 1 - The Real-World Research focuses on evaluating the effectiveness, safety, and economic value of pharmaceutical products based on data generated from daily clinical practices [1] - The National Healthcare Security Administration (NHSA) emphasizes the importance of real-world research as a foundational work for medical insurance decision-making [1] - The NHSA plans to conduct evaluations every two years for negotiated drugs to ensure their benefits align with expectations [1] Group 2 - The NHSA aims for each credible evaluation point to participate in at least one real-world comprehensive value assessment of a drug, consumable, or medical service by 2026 [2] - The initiative is expected to generate demonstrable results that can withstand scrutiny and be applied in practical scenarios [2]